<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NAFCILLINÂ - nafcillin sodiumÂ injection, powder, for solutionÂ </strong><br>AuroMedics Pharma LLC<br></p></div>
<h1>NAFICILLIN FOR INJECTION, USP<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_2"></a><a name="section-1"></a><p></p>
<h1>For Intramuscular or Intravenous Injection</h1>
<br><p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of nafcillin for injection and other antibacterial drugs, nafcillin for injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<br><p class="First">Nafcillin for injection, USP is a semisynthetic penicillin derived from the penicillin nucleus, 6-aminopenicillanic acid. The chemical name of nafcillin sodium is Monosodium (2<span class="Italics">S</span>,5<span class="Italics">R</span>,6<span class="Italics">R</span>)-6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylate monohydrate. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase). The structural formula of nafcillin sodium is as follows:</p>
<br><div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90717878-64cb-4ffc-90bc-7b4e81e3d1cd&amp;name=nafcillin-str.jpg"></div>
<p>Nafcillin for injection, USP for the intramuscular or intravenous route of administration, contains nafcillin sodium as a sterile white to yellowish-white powder for reconstitution. The pH of the reconstituted solution is 6.0 to 8.5. Nafcillin for injection, USP contains nafcillin sodium as the monohydrate equivalent to 1 gram or 2 grams of nafcillin per vial and is buffered with 40 mg sodium citrate per gram. The sodium content is 65.78 mg [2.9 mEq] per gram.</p>
<span class="Underline"></span>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<br><p class="First">In a study of five healthy adults administered a single 500 mg dose of nafcillin by intravenous injection over seven minutes, the mean plasma concentration of the drug was approximately 30 mcg/mL at 5 minutes after injection. The mean area under the plasma concentration-versus-time curve (AUC) for nafcillin in this study was 18.06 mcgâ€¢h/mL.<br><br>The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.<br><br>In contrast to the other penicillinase-resistant penicillins, only about 30% of nafcillin is excreted as unchanged drug in the urine of normal volunteers, and most within the first six hours. Nafcillin is primarily eliminated by nonrenal routes, namely hepatic inactivation and excretion in the bile.<br><br>Nafcillin binds to serum proteins, mainly albumin. The degree of protein binding reported for nafcillin is 89.9 Â± 1.5%. Reported values vary with the method of study and the investigator.<br><br>The concurrent administration of probenecid with nafcillin increases and prolongs plasma concentrations of nafcillin. Probenecid significantly reduces the total body clearance of nafcillin with renal clearance being decreased to a greater extent than nonrenal clearance.<br><br>The penicillinase-resistant penicillins are widely distributed in various body fluids, including bile, pleural, amniotic and synovial fluids. With normal doses insignificant concentrations are found in the aqueous humor of the eye. High nafcillin CSF levels have been obtained in the presence of inflamed meninges.<br><br><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> does not appreciably affect the serum half-life of nafcillin; therefore, no modification of the usual nafcillin dosage is necessary in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> with or without hemodialysis. Hemodialysis does not accelerate the rate of clearance of nafcillin from the blood.<br><br>A study which assessed the effects of cirrhosis and <span class="product-label-link" type="condition" conceptid="201066" conceptname="Obstruction of bile duct">extrahepatic biliary obstruction</span> in man demonstrated that the plasma clearance of nafcillin was significantly decreased in patients with hepatic dysfunction. In these patients with cirrhosis and extrahepatic obstruction, nafcillin excretion in the urine was significantly increased from about 30 to 50% of the administered dose, suggesting that <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> superimposed on <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> could further decrease nafcillin clearance.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<br><p class="First">Intramuscular injections of nafcillin sodium 1 gram produced peak serum levels in 0.5 to 1 hour of 7.61 mcg/mL. The degree of protein binding reported has been 89.9 +/-1.5%. With normal doses nafcillin is found in therapeutic concentrations in the pleural, bile, and amniotic fluids. Insignificant concentrations are found in the cerebrospinal fluid and aqueous humor. Blood concentrations may be tripled by the concurrent use of probenecid. Clinical studies with nafcillin sodium in infants under three days of age and prematures have revealed high blood levels and slower rates of urinary excretion than in older children and adults. A high concentration of nafcillin sodium is excreted via the bile. About 30% of an intramuscular dose is excreted in the urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-3.2"></a><p></p>
<h2>Microbiology</h2>
<br><p class="First">Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall. The drugs in this class are highly resistant to inactivation by staphylococcal penicillinase and are active against penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus </span><span class="Italics">aureus</span>. The penicillinase-resistant penicillins are active <span class="Italics">in vitro</span> against a variety of other bacteria.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1.1"></a><a name="section-3.2.1"></a><p></p>
<h3>Susceptibility Test Methods</h3>
<br><p class="First">When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1.1.1"></a><a name="section-3.2.1.1"></a><p></p>
<h4>Dilution Techniques</h4>
<br><p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure based on dilution method<span class="Sup">1,2</span> (broth, agar or microdilution) or equivalent. It has been reported that determination of susceptibility or resistance of a microorganism to all penicillinase-resistant penicillins, including nafcillin, may be deduced by testing microorganisms against either oxacillin or cefoxitin.<span class="Sup">2 </span>For this reason, routine dilution testing of nafcillin is not advised and susceptibility to nafcillin should be determined by dilution using standardized inoculum and concentrations of oxacillin according to the criteria in table 1.<span class="Sup">1,2</span>Â </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 1: Staphylococcus aureus MIC Susceptibility Test Interpretive Criteria for Oxacillin<span class="Sup">a</span></span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule">Â </th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Minimum Inhibitory <br>Oxacillin Concentrations <br>(mcg/mL)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Pathogen</th>
<th class="Lrule Rrule Toprule" align="center">Susceptible (S)</th>
<th class="Lrule Rrule Toprule" align="center">Resistant (R)</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a </span><span class="Italics">Staphylococcus aureus</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> found to be â€œSusceptibleâ€? or â€œResistantâ€? to oxacillin by dilution testing can be considered to be â€œSusceptibleâ€? or "Resistant" to nafcillin.<br>
</td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Italics">Staphylococcus aureus</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤2<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥4<br>
</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1.1.2"></a><a name="section-3.2.1.2"></a><p></p>
<h4>Diffusion Techniques</h4>
<br><p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3</span> requires the use of standardized inoculum concentrations. It has been reported that determination of susceptibility or resistance of a microorganism to all penicillinase-resistant penicillins, including nafcillin, may be deduced by testing microorganisms against either oxacillin or cefoxitin.<span class="Sup">2</span> Disk diffusion results using cefoxitin have been shown to be more reproducible than those obtained with oxacillin,<span class="Sup">4,5</span> therefore cefoxitin is the preferred reagent for testing nafcillin susceptibility by diffusion. Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 microgram cefoxitin disk should be interpreted according to the following criteria in Table 2. </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 2: Staphylococcus aureus Disk Diffusion Susceptibility Test Interpretive Criteria for Nafcillin Using a 30 mcg Cefoxitin Disk<span class="Sup">a</span></span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center">Â </th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Disk Diffusion Diameters (mm)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Pathogen</th>
<th class="Lrule Rrule Toprule" align="center">Susceptible (S)</th>
<th class="Lrule Rrule Toprule" align="center">Resistant (R)</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">a </span><span class="Italics">Staphylococcus aureus</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> found to be â€œSusceptibleâ€? or â€œResistantâ€? to cefoxitin by disk diffusion can be considered to be â€œSusceptibleâ€? or â€œResistantâ€? to nafcillin.<br>
</td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â Staphylococcus aureus</span><br>
</td>
<td class="Rrule" align="center" valign="top">â‰¥ 22<br>
</td>
<td class="Rrule" align="center" valign="top">â‰¤ 21<br>
</td>
</tr></tbody>
</table>
<br><p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in blood. A report of â€œResistantâ€? indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.<br><br>Measurement of MIC or MBC and achieved antimicrobial compound concentrations may be appropriate to guide therapy in some <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (See <span class="Bold"><a href="#Section_2">CLINICAL PHARMACOLOGY</a></span> section for further information on drug concentrations achieved in infected body sites and other pharmacokinetic properties of this antimicrobial drug product.)<br><br><span class="Italics">Quality Control</span><br><br>Standardized susceptibility test procedures require the use of laboratory control microorganisms to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. Appropriate quality control organisms and acceptable corresponding ranges of oxacillin MICs obtained by dilution testing or inhibition zones around 30 mcg cefoxitin disks are provided in Table 3.Â Â  </p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="614">
<caption><span>Table 3: In Vitro Susceptibility Test Quality Control Ranges for Oxacillin and Cefoxitin 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Organism (ATCC #)</th>
<th class="Lrule Rrule Toprule" align="center">Oxacillin MIC<br>range (mcg/mL)</th>
<th class="Lrule Rrule Toprule" align="center">Cefoxitin disk <br>diffusion range (mm)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â Staphylococcus aureus</span> (29213)<br>
</td>
<td class="Rrule" align="center" valign="top">0.12 - 0.5<br>
</td>
<td class="Rrule" align="center" valign="top">Not applicable<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Italics">Â Staphylococcus aureus</span> (25923)<br>
</td>
<td class="Rrule" align="center" valign="top">Not applicable<br>
</td>
<td class="Rrule" align="center" valign="top">23 - 29<br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<br><p class="First">Nafcillin for injection, USP is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see <span class="Bold"><span class="Bold"><a href="#Section_2.1.1">CLINICAL PHARMACOLOGY - Susceptibility Test Methods</a></span></span>).<br><br>Nafcillin for injection, USPÂ may be used to initiate therapy in suspected cases of resistant <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span> prior to the availability of susceptibility test results. Nafcillin for injection, USPÂ should not be used in <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is due to an organism other than a resistant <span class="Italics">Staphylococcus</span>, therapy should not be continued with nafcillin for injection, USP.<br><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of nafcillin for injection, USPÂ and other antibacterial drugs, nafcillin for injection, USPÂ should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<br><p class="First">A history of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reaction to any penicillin is a contraindication.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Section_5"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<br><p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with nafcillin, careful inquiry should be made concerning previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to penicillins, cephalosporins, or other allergens. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, nafcillin should be discontinued and appropriate therapy instituted. Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated.<br><br><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including nafcillin for injection, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.<span class="Italics"><br><br>C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.Â <br><br>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="Section_6.1"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<br><p class="First">Nafcillin should generally not be administered to patients with a history of sensitivity to any penicillin.<br><br>Penicillin should be used with caution in individuals with histories of significant allergies and/or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Whenever <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy. The use of antibiotics may result in overgrowth of nonsusceptible organisms. If new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria or fungi occur, the drug should be discontinued and appropriate measures taken.<br><br>The liver/biliary tract is the primary route of nafcillin clearance. Caution should be exercised when patients with concomitant <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> and renal dysfunction are treated with nafcillin. Serum levels should be measured and the dosage adjusted appropriately to avoid possible neurotoxic reactions associated with very high concentrations (see <span class="Bold"><a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span>).<br><br>Prescribing nafcillin for injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_6.2"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<br><p class="First">Patients should be counseled that antibacterial drugs including nafcillin for injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When nafcillin for injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment andÂ (2) increase the likelihood that bacteria will develop resistance and will not be treatable by nafcillin forÂ injection or other antibacterial drugs in the future.<br><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Section_6.3"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Bacteriologic studies to determine the causative organisms and their susceptibility to the penicillinase-resistant penicillins should be performed (see <a href="#Section_2.1">CLINICAL PHARMACOLOGY: Microbiology</a>). In the treatment of suspected <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span>, therapy should be changed to another active agent if culture tests fail to demonstrate the presence of staphylococci.<br><br>Periodic assessment of organ system function including renal, hepatic, and hematopoietic should be made during prolonged therapy with nafcillin.<br><br>White blood cell and differential cell counts should be obtained prior to initiation of therapy and periodically during therapy with nafcillin.<br><br>Periodic urinalysis, blood urea nitrogen, and creatinine determinations should be performed during therapy with the nafcillin and dosage alterations should be considered if these values become elevated. If any impairment of renal function is suspected or known to exist, a reduction in the total dosage should be considered and blood levels monitored to avoid possible neurotoxin reactions (See <a href="#Section_10">DOSAGE AND ADMINISTRATION</a>).<br><br><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and SGPT values should be obtained periodically during therapy to monitor for possible liver function abnormalities.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_6.4"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<br><p class="First">Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.<br><br>Nafcillin in high dosage regimens, i.e., 2 grams every 4 hours, has been reported to decrease the effects of warfarin. When nafcillin and warfarin are used concomitantly, the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be closely monitored and the dose of warfarin adjusted as necessary. This effect may persist for up to 30 days after nafcillin has been discontinued.<br><br>Nafcillin when administered concomitantly with cyclosporine has been reported to result in subtherapeutic cyclosporine levels. The nafcillin-cyclosporine interaction was documented in a patient during two separate courses of therapy. When cyclosporine and nafcillin are used concomitantly in organ transplant patients, the cyclosporine levels should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="Section_6.5"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<br><p class="First">Nafcillin in the urine can cause a false-positive urine reaction for protein when the sulfosalicyclic acid test is used, but not with the dipstick.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<br><p class="First">No long-term animal studies have been conducted with these drugs. Studies on reproduction (nafcillin) in rats and mice reveal no fetal or maternal abnormalities before conception and continuously through weaning (one generation).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_6.7.1"></a><a name="section-7.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<br><p class="First"><span class="Italics">Pregnancy Category B<br>Â <br></span>Reproduction studies have been performed in the mouse with oral doses up to 20 times the human dose and orally in the rat at doses up to 40 times the human dose and have revealed no evidence of impaired fertility or harm to the rodent fetus due to nafcillin. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, nafcillin should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_6.9"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<br><p class="First">Penicillins are excreted in human milk. Caution should be exercised when penicillins are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_6.10"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<br><p class="First">The liver/biliary tract is the principal route of nafcillin elimination. Because of immature hepatic and renal function in pediatric patients, nafcillin excretion may be impaired, with abnormally high serum levels resulting. Serum levels should be monitored and the dosage adjusted appropriately. There are no approved pediatric patient dosage regimens for intravenous nafcillin. Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_6.11"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<br><p class="First">Clinical studies of nafcillin for injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.<br><br>Nafcillin for injection contains 65.78 mg (2.9 mEq) of sodium per gram. At the usual recommended doses, patients would receive between 197.34 and 394.68 mg/day (8.58 and 17.16 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<br><p class="First"><span class="Bold">Body as a Whole</span><br><br>The reported incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to penicillins ranges from 0.7 to 10 percent (see <span class="Bold"><a href="#Section_5">WARNINGS</a></span>). Sensitization is usually the result of treatment but some individuals have had immediate reactions to penicillin when first treated. In such cases, it is thought that the patients may have had prior exposure to the drug via trace amounts present in milk or vaccines.<br><br>Two types of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to penicillin are noted clinically, immediate and delayed.<br><br>Immediate reactions usually occur within 20 minutes of administration and range in severity from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> to <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Such immediate <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> are very rare (see <span class="Bold"><a href="#Section_5">WARNINGS</a></span>) and usually occur after parenteral therapy but have occurred in patients receiving oral therapy. Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Although <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occasionally occur, fatality is uncommon.<br><br>Delayed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to penicillin therapy usually occur after 48 hours and sometimes as late as 2 to 4 weeks after initiation of therapy. Manifestations of this type of reaction include <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like symptoms (i.e., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>) and various <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, black or hairy tongue, and other symptoms of <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> may occur, especially during oral penicillin therapy.<span class="Bold"><br><br>Local Reactions<br>Â <br></span><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, and occasional skin <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> at the injection site have occurred with intravenous administration of nafcillin (see <span class="Bold"><a href="#Section_10">DOSAGE AND ADMINISTRATION</a></span>). Severe tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> with <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">sloughing</span> secondary to subcutaneous <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of nafcillin has been reported.<span class="Bold"><br><br>Nervous System Reactions<br>Â <br></span>Neurotoxic reactions similar to those observed with penicillin G could occur with large intravenous or intraventricular doses of nafcillin especially in patients with concomitant <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> and renal dysfunction (see <span class="Bold"><a href="#Section_6">PRECAUTIONS</a></span>).<span class="Bold"><br><br>Urogenital Reactions<br>Â <br></span>Renal tubular damage and interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> have been associated infrequently with the administration of nafcillin. Manifestations of this reaction may include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.<span class="Bold"><br><br>Gastrointestinal Reactions<br>Â <br></span><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with the use of nafcillin. The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment (see <span class="Bold"><a href="#Section_5">WARNINGS</a></span>).<span class="Bold"><br><br>Metabolic Reactions<br>Â <br></span><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> have been associated with the use of nafcillin.<br><span class="Bold"><br>To report SUSPECTED ADVERSE EVENTS, contact FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch.</span></span></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<br><p class="First">Neurotoxic reactions similar to those observed with penicillin G may arise with intravenous doses of nafcillin especially in patients with concomitant <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> and renal dysfunction (see <span class="Bold"><a href="#Section_6">PRECAUTIONS</a></span>).<br><br>In the case of overdosage, discontinue nafcillin, treat symptomatically and institute supportive measures as required. Hemodialysis does not increase the rate of clearance of nafcillin from the blood.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<br><p class="First">Nafcillin for injection is available for intramuscular and intravenous use. The penicillinase-resistant penicillins are available for oral administration and for intramuscular and intravenous injection. The sodium salts of methicillin, oxacillin, and nafcillin may be administered parenterally and the sodium salts of cloxacillin, dicloxacillin, oxacillin, and nafcillin are available for oral use. The usual I.V. dosage for adults is 500 mg every 4 hours. For severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, 1 gram every 4 hours is recommended. Administer slowly over at least 30 to 60 minutes to minimize the risk of vein irritation and <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="600">
<caption><span>RECOMMENDED DOSAGE FOR NAFCILLIN FOR INJECTION, USP 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Drug</th>
<th class="Lrule Rrule Toprule" align="center">Adults</th>
<th class="Lrule Rrule Toprule" align="center">Infants and<br>Children &lt;40 kg <br>(88 lbs)</th>
<th class="Lrule Rrule Toprule" align="center">Other<br>Recommendations</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">Â Nafcillin<br>
</td>
<td class="Rrule" valign="top">Â 500 mg IM every<br>Â 4 to 6 hours. <br>Â IV every 4 hours<br>
</td>
<td class="Rrule" valign="top">Â 25 mg/kg IM twice daily<br>
</td>
<td class="Rrule" valign="top">Â Neonates 10 mg/kg IM twice daily<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â Nafcillin<br>
</td>
<td class="Rrule" valign="top">Â 1 gram IM or IV every <br>Â 4 hours (severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>)<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
</tbody>
</table>
<br><p>Bacteriologic studies to determine the causative organisms and their susceptibility to nafcillin should always be performed. Duration of therapy varies with the type and severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> as well as the overall condition of the patient; therefore, it should be determined by the clinical and bacteriological response of the patient. In severe <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span>, therapy with nafcillin should be continued for at least 14 days. Therapy should be continued for at least 48 hours after the patient has become afebrile, asymptomatic, and cultures are negative. The treatment of <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> and <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span> may require a longer duration of therapy.<br><br>Concurrent administration of the penicillinase-resistant penicillins and probenecid increases and prolongs serum penicillin levels. Probenecid decreases the apparent volume of distribution and slows the rate of excretion by competitively inhibiting renal tubular secretion of penicillin. Nafcillin-probenecid therapy is generally limited to those <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> where very high serum levels of nafcillin are necessary.<br><br>No dosage alterations are necessary for patients with renal dysfunction, including those on hemodialysis. Hemodialysis does not accelerate nafcillin clearance from the blood.<br><br>For patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, measurement of nafcillin serum levels should be performed and dosage adjusted accordingly.<br><br>With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.<br><br>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.<br><br>Do not add supplementary medication to nafcillin.<br><br>Oral preparations of the penicillinase-resistant penicillins should not be used as initial therapy in serious life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (see <span class="Bold"><a href="#Section_6.1">PRECAUTIONS, General</a></span>). Oral therapy with the penicillinase-resistant penicillins may be used to follow-up the previous use of a parenteral agent as soon as the clinical condition warrants. For intramuscular gluteal injections, care should be taken to avoid sciatic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve injury</span>. With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.<br><span class="Bold"><br>Directions for Use</span><br><br>For Intramuscular Use<br><br>Reconstitute with Sterile Water for Injection, USP, 0.9% Sodium Chloride Injection, USP or Bacteriostatic Water for Injection, USP (with benzyl alcohol or parabens); add 3.4 mL to the 1 g vial for 4 mL resulting solution; 6.6 mL to the 2 g vial for 8 mL resulting solution. All reconstituted vials have a concentration of 250 mg per mL.<br><br>The clear solution should be administered by deep intragluteal injection immediately after reconstitution.<br><br>Reconstituted Stability<br><br>Reconstitute with the required amount of Sterile Water for Injection, USP, 0.9% Sodium Chloride Injection, USP or Bacteriostatic Water for Injection, USP (with benzyl alcohol or parabens). The resulting solutions are stable for 3 days at room temperature or 7 days under refrigeration and 90 days frozen.<br><br>For Direct Intravenous Use<br><br>The required amount of drug should be diluted in 15 to 30 mL of Sterile Water for Injection, USP or Sodium Chloride Injection, USP and injected over a 5- to 10-minute period. This may be accomplished through the tubing of an intravenous infusion if desirable.<br><br>For Administration by Intravenous Drip <br><br>Reconstitute as directed above (For Intravenous Use) prior to diluting with Intravenous Solution.</p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="602">
<caption><span>STABILITY PERIODS FOR NAFCILLIN FOR INJECTION, USP<span class="Sup">*</span></span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">Concentration<br>mg/mL</th>
<th class="Lrule Rrule Toprule" align="center">Sterile Water for<br>Injection USP</th>
<th class="Lrule Rrule Toprule" align="center">Sodium Chloride<br>Injection USP (0.9%)</th>
<th class="Lrule Rrule Toprule" align="center">Sodium Lactate<br>Solution USP (M/6 Molar)</th>
<th class="Lrule Rrule Toprule" align="center">Dextrose Injection<br>USP (5%)</th>
<th class="Lrule Rrule Toprule" align="center">Dextrose and Sodium<br>Chloride Injection USP<br>(5% Dextrose and<br>0.45% Sodium Chloride)</th>
<th class="Lrule Rrule Toprule" align="center">Invert Sugar<br>Injection USP<br>(10%)</th>
<th class="Lrule Rrule Toprule" align="center">Lactated Ringerâ€™s<br>Injection USP </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="8">* IMPORTANT: This chemical stability information in no way indicates that it would be acceptable practice to use this product well after the preparation time. Good professional practice suggests that a product should be used as soon after preparation as feasible.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="8" valign="top">ROOM TEMPERATURE (25ÂºC)<br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â 10-200<br>
</td>
<td class="Rrule" valign="top">Â 24 Hrs<br>
</td>
<td class="Rrule" valign="top">Â 24 Hrs<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â 30<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â 24 Hrs<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â 2-30<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â 24 Hrs<br>
</td>
<td class="Rrule" valign="top">Â 24 Hrs<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â 10-30<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â 24 Hrs<br>
</td>
<td class="Rrule" valign="top">Â 24 Hrs<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="8" valign="top">REFRIGERATION (4ÂºC)<br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â 10-200<br>
</td>
<td class="Rrule" valign="top">Â 7 Days<br>
</td>
<td class="Rrule" valign="top">Â 7 Days<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â 10-30<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â 7 Days<br>
</td>
<td class="Rrule" valign="top">Â 7 Days<br>
</td>
<td class="Rrule" valign="top">Â 7 Days<br>
</td>
<td class="Rrule" valign="top">Â 7 Days<br>
</td>
<td class="Rrule" valign="top">Â 7 Days<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="8" valign="top">FROZEN (-15ÂºC)<br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â 250<br>
</td>
<td class="Rrule" valign="top">Â 90 Days<br>
</td>
<td class="Rrule" valign="top">Â 90 Days<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â 10-250<br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â <br>
</td>
<td class="Rrule" valign="top">Â 90 Days<br>
</td>
<td class="Rrule" valign="top">Â 90 Days<br>
</td>
<td class="Rrule" valign="top">Â 90 Days<br>
</td>
<td class="Rrule" valign="top">Â 90 Days<br>
</td>
<td class="Rrule" valign="top">Â 90 Days<br>
</td>
</tr>
</tbody>
</table>
<br><p>Only those solutions listed above should be used for the intravenous infusion of nafcillin sodium. The concentration of the antibiotic should <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> within the range specified. The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of nafcillin is administered before the drug loses its stability in the solution in use.<br><br>There is no clinical experience available on the use of this agent in neonates or infants for this route of administration.<br><br>This route of administration should be used for relatively short-term therapy (24 to 48 hours) because of the occasional occurrence of <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> particularly in elderly patients.<br><br>If another agent is used in conjunction with nafcillin therapy, <span class="Bold">it should not be physically mixed</span> with nafcillin but should be administered separately.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<br><p class="First">Each vial of nafcillin for injection, USP contains nafcillin sodium equivalent to 1 gram or 2 grams of nafcillin.<br><br>Nafcillin for Injection, USP is a sterile, white to yellowish-white powder supplied in vials as follows:<br><br>Nafcillin for Injection USP, 1 g vials inÂ aÂ Box ofÂ 10Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 55150-122-15<br>Nafcillin for Injection USP, 2 g vials inÂ aÂ Box ofÂ 10Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 55150-123-15<span class="Bold"><br><br>Store at </span>20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]<br><br>The vial stopper is not made with natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="Section_14"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition.</span> CLSI Document M07-A8 (ISBN 1-56238-689-1). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.</li>
<li>Clinical and Laboratory Standards Institute. <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement.</span> CLSI Document M100S21 (ISBN 1-56238-742-1). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2011.</li>
<li>Clinical and Laboratory Standards Institute. <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Tenth Edition.</span> CLSI Document M02-A10 (ISBN 1-56238-688-3). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.</li>
<li>Palazzo ICV, Darini ALC. Evaluation of methods for detecting oxacillin resistance in coagulase-negative staphylococci including cefoxitin disc diffusion. FEMS Microbiol Lett 2006;257:299-305.</li>
<li>Swenson JM, Tenover FC; Cefoxitin Disk Study Group. Results of disk diffusion testing with cefoxitin correlate with presence of mecA in <span class="Italics">Staphylococcus</span> spp. J Clin Microbiol 2005;43:3818-23.Â </li>
</ol>
<br><p class="First">Manufactured for:<br><span class="Bold">AuroMedics Pharma LLC</span><br>6 Wheeling Road<br>Dayton, NJ 08810<br><br>Manufactured by:<br><span class="Bold">Aurobindo Pharma Limited</span><br>Hyderabad-500 072, India<br><br>Issued: September2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_17"></a><a name="section-13"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 g Vial Label</h1>
<br><p class="First"><span class="Bold">NDC 55150-122-15</span><br><span class="Bold">NAFCILLIN FOR<br>INJECTION, USP</span><br><span class="Bold">1 gram/vial</span><br><span class="Bold">Sterile</span><br>This vial contains nafcillin sodium as the monohydrate, equivalent to 1 g nafcillin. <br>Each gram contains 65.78 mgÂ [2.9 mEq] sodium and is buffered with 40 mg sodium citrate.<br><span class="Bold">Buffered - for Intramuscular </span><br><span class="Bold">ot Intravenous use<br>Rx only</span><br><span class="Bold">AUROMEDICS<br><br><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL â€“ 1 g (Vial Label)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90717878-64cb-4ffc-90bc-7b4e81e3d1cd&amp;name=nafcillin-fig1.jpg"></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-14"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 g Box (10 Vial)</h1>
<br><p class="First"><span class="Bold">10 x 1 gram vialsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC 55150-122-15</span><br><span class="Bold">NAFCILLIN FOR INJECTION, USP</span><br><span class="Bold">1 gram/vial</span><br><span class="Bold">Sterile</span><br>This vial contains nafcillin sodium as the monohydrate, equivalent to 1 g nafcillin. Each<br>gram contains 65.78 mgÂ [2.9 mEq] sodium and is buffered with 40 mg sodium citrate.<br><span class="Bold">Buffered - for Intramuscular or Intravenous UseÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â </span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">Rx only</span><br><span class="Bold">AUROMEDICS<br><br></span></p>
<div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL â€“ 1 g Box (10 Vial)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90717878-64cb-4ffc-90bc-7b4e81e3d1cd&amp;name=nafcillin-fig2.jpg"></div>
<br><br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-15"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 2 g Vial Label</h1>
<br><p class="First"><span class="Bold">NDC 55150-123-15</span><br><span class="Bold">NAFCILLIN FOR <br>INJECTION, USP</span><br><span class="Bold">2Â grams/vial</span><br><span class="Bold">Sterile</span><br>This vial contains nafcillin sodium as the monohydrate, equivalent toÂ 2 g nafcillin. <br>Each gram contains 65.78 mgÂ [2.9 mEq] sodium and is buffered with 40 mg sodium citrate.<br><span class="Bold">Buffered - for <span class="Bold">Intramuscular <br>or Intravenous Use</span>Â </span><br><span class="Bold">Rx only</span><br><span class="Bold">AUROMEDICS<br><br></span></p>
<div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL â€“ 2 g (Vial Label)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90717878-64cb-4ffc-90bc-7b4e81e3d1cd&amp;name=nafcillin-fig3.jpg"></div>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_20"></a><a name="section-16"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 2 g Box (10 Vial)</h1>
<br><p class="First"><span class="Bold">10 xÂ 2 gram vialsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NDC 55150-123-15</span><br><span class="Bold">NAFCILLIN FOR INJECTION, USP</span><br><span class="Bold">2Â grams/vial</span><br><span class="Bold">Sterile</span><br>This vial contains nafcillin sodium as the monohydrate, equivalent toÂ 2 g nafcillin. Each<br>gram contains 65.78 mgÂ [2.9 mEq] sodium and is buffered with 40 mg sodium citrate.<br><span class="Bold">Buffered - for <span class="Bold">Intramuscular or Intravenous Use</span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â </span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">Rx only</span><br><span class="Bold">AUROMEDICS<br><br></span></p>
<div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL â€“ 2 g Box (10 Vial)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90717878-64cb-4ffc-90bc-7b4e81e3d1cd&amp;name=nafcillin-fig4.jpg"></div>
<br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NAFCILLINÂ 		
					</strong><br><span class="contentTableReg">nafcillin sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55150-122</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NAFCILLIN SODIUM</strong> (NAFCILLIN) </td>
<td class="formItem">NAFCILLIN</td>
<td class="formItem">1Â g Â inÂ 4Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Yellowish-White) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55150-122-15</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091613</td>
<td class="formItem">12/26/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NAFCILLINÂ 		
					</strong><br><span class="contentTableReg">nafcillin sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55150-123</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NAFCILLIN SODIUM</strong> (NAFCILLIN) </td>
<td class="formItem">NAFCILLIN</td>
<td class="formItem">2Â g Â inÂ 8Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Yellowish-White) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55150-123-15</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">8 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091613</td>
<td class="formItem">12/26/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>AuroMedics Pharma LLC
							(968961354)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917634</td>
<td class="formItem">API MANUFACTURE(55150-122, 55150-123)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917683</td>
<td class="formItem">ANALYSIS(55150-122, 55150-123), MANUFACTURE(55150-122, 55150-123)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e31685cd-5b05-4c97-a668-e51c6277e47d</div>
<div>Set id: 90717878-64cb-4ffc-90bc-7b4e81e3d1cd</div>
<div>Version: 5</div>
<div>Effective Time: 20131230</div>
</div>
</div>Â <div class="DistributorName">AuroMedics Pharma LLC</div></p>
</body></html>
